People · Operator
Named in public records as an officer, director or promoter · active 2010–2022 · Biotechnology, Pharma, Other Technology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Mediar Therapeutics, Inc. | — | Biotechnology | Series C | $127.9M | $194.6M | 2019 |
| Alessa Therapeutics, Inc. | — | Pharma | Series B | $31.6M | $129.5M | 2019 |
| Veritas Genetics International Ltd. | — | Other Technology | Series B | $30.3M | $141.4M | 2016 |
| Mitokinin, Inc. | — | Biotechnology | Series A | $9.5M | $180.8M | 2018 |
| Photoswitch Biosciences, Inc. | — | Biotechnology | Pre-Seed | $1.5M | $27.6M | 2017 |
| Castlewood Surgical Inc | — | Other Health Care | Pre-Seed | $1.4M | $12.6M | 2010 |
Peter Parker at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter Parker on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Douglas Crawford | 3 | 8 |
| Doug Crawford | 2 | 3 |
| Richard Lim | 1 | 14 |
| Judith Li | 1 | 8 |
| Cam Gallagher | 1 | 7 |
| Meredith Fisher | 1 | 6 |
| Richard Upton | 1 | 6 |
| Wolfgang Daum | 1 | 5 |
| Michael Baran | 1 | 4 |
| Brian Hubbard | 1 | 4 |
| Nandita Shangari | 1 | 4 |
| John Maroney | 1 | 3 |
| Ann Merrifield | 1 | 3 |
| Allan Marchington | 1 | 3 |
| Zachary Collins | 1 | 3 |
| David De Graaf | 1 | 3 |
| Mirza Cifric | 1 | 3 |
| Johannes Fruehauf | 1 | 2 |
| Andreas Jurgeit | 1 | 2 |
| Steve Tregay | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.